UBS raised its target price for Kelun Botai Bio (06990.HK) to HK$678 from HK$667 and reiterated a Buy rating. UBS said H1 product revenue was 657 mln yuan, above its expectation. The bank lifted EPS forecasts for 2026–28 to 2.41, 2.09 and 8.29 yuan p

2026-08-18

UBS raised its target price for Kelun Botai Bio (06990.HK) to HK$678 from HK$667 and reiterated a Buy rating. UBS said H1 product revenue was 657 mln yuan, above its expectation. The bank lifted EPS forecasts for 2026–28 to 2.41, 2.09 and 8.29 yuan per share and now projects 2026 product revenue of 14.3 bln yuan.